Chairman, Division of Gastroenterology and Hepatology, Antwerp University Hospital
Global Engage hosted the 5th Global NASH Congress on the 26-27 May 2022 in London.
Endorsed by the:
An increasing number of people are being diagnosed with nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) each year, and the primary method of treatment is weight loss. With no approved medicines on the market, the drug development race is intensifying. The pathogenesis of NASH is still not fully understood, and definitive diagnostic methods are invasive, so development has been slow.
However, promising developments in research will hopefully bolster drug development and other methods
of treatment. Examples of such developments include improved in vivo liver models, non-invasive diagnostic biomarkers and a better understanding of the disease’s mechanisms. This year’s congress focused on these exciting advancements, as well as on the challenges of preclinical and clinical research in NASH. There was also sessions covering regulation and business development, as well as a showcase of the most promising therapeutics in development.
Although affected by the Omicron spike, the meeting still attracted experts working in all areas of nonalcoholic steatohepatitis to examine the latest research and development in pathogenesis, diagnosis and treatment of the disease. The event provided an excellent opportunity to meet and collaborate with senior representatives from industry, hospitals and universities. With many people forced into joining us online, on the conference’s Digital Day, we look forward to returning to a 100% live and in person meeting in 2023!
“I really enjoyed the scientific content of the conference with news from providers and Pharma organisations.” Delegate Pharma Company
“There was a good variety of speakers & content with ample networking opportunities” NHS Delegate
“A very good spread of content with topics that were applicable to a wide audience.”Academic delegate
“Well organised, varied content covering the main aspects of NASH and drug development.” Speaker
“I appreciated the broad spectrum of areas within NASH from clinical trials and biomarker to scientific new projects. The conference provided a nice overview of the field as of today.” Sponsor
Professor in Pathology, Chair, Pathology Department, Beaujon Hospital, Clichy, Inserm